New Hope for Breast Cancer Patients: Research Backed by Al Jalila Reveals Causes of Chemotherapy Resistance

New research supported by the Al Jalila Foundation has identified a key genetic mechanism behind chemotherapy resistance in triple-negative breast cancer, offering potential pathways for more effective treatments. The study, conducted in Dubai and announced on April 23, 2026, focused on the role of the FOXC1 gene in treatment resistance, a major obstacle in oncology that often leads to cancer recurrence.

The research, titled “The Role of the FOXC1 Gene in Stimulating Aggressive Oncogenic Programs and Chemotherapy Resistance in Triple-negative Breast Cancer through Modulation of Chromatin Availability,” was led by Dr. Shakhzada Ibragimova as part of her PhD work at Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU). By examining how specific genes influence cancer behavior and progression, the study aims to develop targeted therapies that address resistance at its source.

Triple-negative breast cancer, which lacks estrogen receptors, progesterone receptors, and HER2 protein, accounts for approximately 10–15% of all breast cancer cases and is known for its aggressiveness and limited treatment options. Unlike hormone receptor-positive or HER2-positive subtypes, it does not respond to hormonal therapy or drugs targeting HER2, making chemotherapy a primary treatment modality. However, many patients develop resistance to chemotherapy over time, diminishing its effectiveness and increasing the risk of metastasis.

The FOXC1 gene, a member of the forkhead box (Fox) family of transcription factors, has been implicated in various cancers due to its role in regulating cell differentiation, proliferation, and survival. By identifying the biological pathways through which cancer cells resist chemotherapy, researchers aim to develop precision medicine approaches that could reduce relapse rates and improve patient outcomes.